{"prompt": "['MK-7902', 'PAGE 40', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Abbreviation', 'Expanded Term', 'cLDA', 'constrained longitudinal data analysis', 'CR', 'complete response', 'CRF', 'case report form', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'DMC', 'data monitoring committee', 'DOR', 'duration of response', 'ECG', 'electrocardiogram', 'ECI', 'event of clinical interest', 'EOC', 'Executive Oversight Committee', 'EORTC', 'European Organisation for Research and Treatment of Cancer', 'ePRO', 'electronic patient-reported outcome', 'EQ-5D', 'EuroQoL-5D-5L', 'FAS', 'Full Analysis Set', 'HR', 'hazard ratio', 'HRQoL', 'health-related quality of life', 'HSD', 'Hwang-Shih-DeCani', 'IA', 'interim analysis', 'ICH', 'International Conference on Harmonization', 'iRECIST', 'Modified RECIST 1.1 for Immune-based Therapeutics', 'ITT', 'Intention to Treat', 'NPH', 'Non-proportional Hazards', 'PH', 'Proportional Hazards', 'NSCLC', 'non-small cell lung cancer', 'OR', 'objective response', 'ORR', 'objective response rate', 'OS', 'overall survival', 'PD', 'progressive disease', 'PD-L1', 'programmed cell death ligand 1', 'PFS', 'progression-free survival', 'PH', 'proportional hazards', 'Confidential']['MK-7902', 'PAGE 41', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Abbreviation', 'Expanded Term', 'PK', 'pharmacokinetic', 'PR', 'partial response', 'PRO', 'patient-reported outcomes', 'QLQ-LC13', 'Quality of Life Questionnaire and Lung Cancer Module 13', 'QoL', 'quality of life', 'RECIST 1.1', 'Response Evaluation Criteria in Solid Tumors 1.1', 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'sSAP', 'supplemental statistical analysis plan', 'TPS', 'tumor proportion score', 'TTD', 'time to true deterioration', 'C', 'Confidential']['MK-7902', 'PAGE 42', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', '6.', 'REFERENCES', 'Cocks K, King MT, Velikova G, de Castro G, Martyn St-James M, Fayers PM, et al. Evidence-based', 'guidelines for interpreting change scores for the European organisation for the research and treatment of', 'cancer quality of life questionnaire core 30. Eur J Cancer. 2012 Jul;48(11):1713-21.', 'Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version', 'of EQ-5D (EQ-5D-5L). Quality of life research : an international journal of quality of life aspects of', 'treatment, care and rehabilitation. 2011;20(10):1727-1736.', 'King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of', 'Life Research 1996;5:555-67.', 'Lan, K. K., & DeMetes, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika, 70(3):', '659-63.', 'Liang K, Zeger, S (2000). Longitudinal data analysis of continuous and discrete responses for pre-post', 'designs. Sankhy\u00e3: The Indian Journal of Statistics, 62 (Series B), 134-148.', 'Maringwa JT, Quinten C, King M, et al. Minimal important differences for interpreting health-related', 'quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized', 'controlled trials. Supportive care in cancer : official journal of the Multinational Association of Supportive', 'Care in Cancer. 2011;19(11):1753-1760.', 'Maurer, W., & Bretz, F. (2013). Multiple Testing in Group Sequential Trials using Graphical Approaches.', 'Statistics in Biopharmaceutical Research, 5(4): 311-320.', 'Miettinen, O., & Nurminen, M. (1985). Comparative analysis of two rates. Statistics in Medicine, 4:213-', '226.', \"O'Brien, P. C., & Fleming, T. R. (1979). A Multiple Testing Procedure for Clinical Trials. Biometrics,\", '35(3): 549-556.', 'Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes', 'in health-related quality-of-life scores. J Clin Oncol, 16:139-44.', 'Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and', 'VAS scores in cancer. Health and Quality of Life Outcomes. 2007;5:70.', 'Scott, N. W., Fayers, P. M., Aaronson, N. K., Bottomley, A., Graeff, A. d., Groenvold, M.,', 'Sprangers, M. A. (2008). EORTO QLQ-C30 Reference Values. Retrieved from', 'ttps://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}